CSPC Pharmaceutical Group's (HKG:1093) developed Amphotericin B Liposome for injection was approved for drug registration by the National Medical Products Administration of China, a Monday filing with the Hong Kong Exchange said.
Amphotericin B is a type of polyene antibiotics and is used for the prevention and treatment of invasive fungal diseases.
The drug as compared to its competitors in the market, mainly exists in the liposomal form in the bloodstream, substantially reducing the binding of free amphotericin B to renal tubular epithelial cells, which results in a decrease in infusion reactions, significant reduction in drug nephrotoxicity, shortened administration duration, increase in dosage and improvement of therapeutic index.
The company's shares were up nearly 2% in recent trade.
Price (HKD): $4.64, Change: $+0.070, Percent Change: +1.53%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.